JP2008514203A5 - - Google Patents

Download PDF

Info

Publication number
JP2008514203A5
JP2008514203A5 JP2007533758A JP2007533758A JP2008514203A5 JP 2008514203 A5 JP2008514203 A5 JP 2008514203A5 JP 2007533758 A JP2007533758 A JP 2007533758A JP 2007533758 A JP2007533758 A JP 2007533758A JP 2008514203 A5 JP2008514203 A5 JP 2008514203A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
acid molecule
filovirus
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007533758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008514203A (ja
JP5046941B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/034798 external-priority patent/WO2006037038A1/en
Publication of JP2008514203A publication Critical patent/JP2008514203A/ja
Publication of JP2008514203A5 publication Critical patent/JP2008514203A5/ja
Application granted granted Critical
Publication of JP5046941B2 publication Critical patent/JP5046941B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007533758A 2004-09-27 2005-09-27 エボラ及び他のウイルスに対する防御に最適化されたワクチン Expired - Lifetime JP5046941B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US61388304P 2004-09-27 2004-09-27
US60/613,883 2004-09-27
US67760605P 2005-05-03 2005-05-03
US60/677,606 2005-05-03
US67976705P 2005-05-10 2005-05-10
US60/679,767 2005-05-10
US70169405P 2005-07-22 2005-07-22
US60/701,694 2005-07-22
US71587405P 2005-09-09 2005-09-09
US60/715,874 2005-09-09
PCT/US2005/034798 WO2006037038A1 (en) 2004-09-27 2005-09-27 Optimized vaccines to provide protection against ebola and other viruses

Publications (3)

Publication Number Publication Date
JP2008514203A JP2008514203A (ja) 2008-05-08
JP2008514203A5 true JP2008514203A5 (https=) 2008-11-13
JP5046941B2 JP5046941B2 (ja) 2012-10-10

Family

ID=35695786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007533758A Expired - Lifetime JP5046941B2 (ja) 2004-09-27 2005-09-27 エボラ及び他のウイルスに対する防御に最適化されたワクチン

Country Status (7)

Country Link
US (2) US8101739B2 (https=)
EP (1) EP1797113B1 (https=)
JP (1) JP5046941B2 (https=)
AU (1) AU2005289439B2 (https=)
CA (1) CA2581840C (https=)
IL (1) IL182225A (https=)
WO (1) WO2006037038A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
US7947286B2 (en) 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
US8663981B2 (en) 2008-08-07 2014-03-04 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Optimized promoter sequence
EP2560680B1 (en) * 2010-04-16 2018-11-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Chimpanzee adenoviral vector-based filovirus vaccines
DK2655604T3 (en) * 2010-12-14 2018-08-06 Us Gov Health & Human Services ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES
KR102323287B1 (ko) 2011-10-05 2021-11-05 원드 매터리얼 인코포레이티드 리튬 이온 배터리용 실리콘 나노구조체 활물질, 및 그에 관련된 공정, 조성물, 구성요소 및 디바이스
CA3194125A1 (en) * 2012-04-12 2013-10-17 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
WO2015197820A1 (en) 2014-06-26 2015-12-30 Crucell Holland B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MX2017002890A (es) 2014-09-03 2017-11-13 Bavarian Nordic As Métodos y composiciones para potenciar respuestas inmunitarias.
EP3188752A2 (en) * 2014-09-03 2017-07-12 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
HUE065565T2 (hu) 2014-09-03 2024-06-28 Bavarian Nordic As Módszerek és készítmények filovírus fertõzés elleni védõ immunitás elõidézésére
CA2962849A1 (en) * 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
GB201502209D0 (en) 2015-02-10 2015-03-25 Sec Dep For Health The And Chancellor Masters And Scholars Of The University Of Oxford The And Micro Filovirus therapy
CA2977499C (en) 2015-02-25 2023-10-03 Vanderbilt University Antibody-mediated neutralization of marburg virus
WO2017172622A1 (en) * 2016-03-28 2017-10-05 Integrated Biotherapeutics, Inc. Pan filovirus vaccine compositions and methods of making
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018011198A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
AU2019323115A1 (en) * 2018-08-13 2021-01-28 Janssen Vaccines & Prevention B.V. Stabilized filovirus glycoprotein trimers
WO2022226060A1 (en) * 2021-04-21 2022-10-27 Vanderbilt University Antibody cocktail for treatment of ebolavirus infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
WO1999032147A1 (en) * 1997-12-23 1999-07-01 The Regents Of The University Of Michigan Immunization for ebola virus infection
WO2003028632A2 (en) 2001-10-01 2003-04-10 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of a preventive vaccine for filovirus infection in primates
AU2003232004A1 (en) * 2002-04-30 2003-11-17 The Trustees Of The University Of Pennsylvania Chimeric ebola virus envelopes and uses therefor

Similar Documents

Publication Publication Date Title
JP2008514203A5 (https=)
US10273269B2 (en) High potency immunogenic zika virus compositions
US7528223B2 (en) Antigens encoded by alternative reading frames from pathogenic viruses
US8435535B2 (en) Fusion proteins of HIV regulatory/accessory proteins
JP2008529558A5 (https=)
JP2010500399A5 (https=)
JP2013501038A5 (https=)
JP2008530245A5 (https=)
JP2013500015A5 (https=)
JP2019519252A5 (https=)
JP2004518631A5 (https=)
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses
JP2006506097A5 (https=)
US10729762B2 (en) HIV immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto
JP2004501646A5 (https=)
WO2008154867A1 (fr) Composé immunogénique
JP2009501012A5 (https=)
CN115698295A (zh) 一种疫苗试剂和接种方法
CN103298936A (zh) 具有新型流感病毒来源的血凝素蛋白基因的重组痘苗病毒
JP2011088864A (ja) インフルエンザウイルスに対するベクターワクチン
WO2022127820A1 (zh) 病原样抗原疫苗及其制备方法
JPWO2022246084A5 (https=)
JP5004990B2 (ja) パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
JP2014505700A (ja) 抗原性ｇｌｙ１ポリペプチド
JPWO2023102375A5 (https=)